Image
Practice Point
Anti-HER2 therapy – Combination with neratinib
Consider adding neratinib to high risk ER-positive/HER2-positive patients who complete one year of trastuzumab and remain disease-free.
How this guidance was developed
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.
Anti-HER2 therapy – Combination with neratinib
Practice Point
Consider adding neratinib to high risk ER-positive/HER2-positive patients who complete one year of trastuzumab and remain disease-free.
Principles in action
Patient-centred care
Image
Discuss out of pocket costs
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.